导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 5.29% | 1097/4773 |
| 近一周 | -1.71% | 666/5462 |
| 近一月 | -3.15% | 1575/5421 |
| 近一季 | -5.67% | 1892/5209 |
| 近半年 | -0.31% | 1266/4920 |
| 近一年 | 7.75% | 1264/4366 |
| 近两年 | 48.77% | 1514/2954 |
| 近三年 | 33.99% | 901/2253 |
| 成立以来 | 139.47% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.96% 1400/4961 |
14.15% 1867/5312 |
- - |
- - |
| 2025 | 17.04% 2402/4813 |
-1.02% 2536/3635 |
1.73% 2197/4076 |
14.99% 2849/4524 |
1.08% 1550/4813 |
| 2024 | 13.70% 1114/3463 |
0.07% 1050/2808 |
1.13% 498/3014 |
13.87% 2086/3129 |
-1.33% 1657/3463 |
| 2023 | -5.81% 780/2656 |
3.25% 1231/2280 |
-2.33% 580/2385 |
-2.13% 622/2515 |
-4.57% 1097/2655 |
| 2022 | -22.55% 1073/2207 |
-15.31% 1031/1919 |
4.51% 1006/2016 |
-14.11% 1026/2113 |
1.87% 1105/2208 |
| 2021 | -0.22% 745/1822 |
-2.31% 616/1255 |
8.37% 628/1330 |
-6.35% 917/1466 |
0.64% 1084/1822 |
| 2020 | 58.86% 131/1250 |
-3.42% 301/1028 |
20.14% 284/1067 |
16.88% 128/1164 |
17.14% 135/1184 |
| 2019 | 42.86% 202/1092 |
26.76% 378/754 |
0.51% 169/804 |
1.72% 365/850 |
10.23% 153/918 |
| 2018 | -19.46% 165/834 |
- - |
- - |
- - |
-9.94% 169/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 西部利得沪深300指数增强A VS. 长安沪深300非周期A(740101) |